<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92514">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045654</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-086</org_study_id>
    <nct_id>NCT02045654</nct_id>
  </id_info>
  <brief_title>Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome</brief_title>
  <official_title>Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of decitabine and identify predictors for response to decitabine
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or
           secondary) based on the World Health Organization (WHO) classifications

        -  Survival and response Analysis

        -  Response rate

        -  Overall survival

        -  Leukemia free survival
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>International Working Group (IWG) response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured from the date of decitabine therapy to the date of death or the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>the date of decitabine therapy to the date of death or leukemic transformation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>MDS patients</arm_group_label>
    <description>MDS patients who were treated with decitabine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or
        secondary) based on the World Health Organization (WHO) classifications
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or
             secondary) based on the World Health Organization (WHO) classifications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ho Jang, Pf</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Ho Jang, Pf</last_name>
    <email>jh21.jang@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Hematology Oncology, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ho Jang, M.D.</last_name>
      <phone>82-2-3410-0918</phone>
      <email>smcjunhojang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jun Ho Jang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
